Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: A phase II window study

Journal of Clinical Oncology

Volumn 18, Issue 13, 2000, Pages 2576-2581

  Mantadakis, Elpis ^a   Herrera, Larry ^a   Leavey, Patrick J ^a   Bash, Robert O ^a   Winick, Naomi J ^a   Kamen, Barton A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; EWING SARCOMA; FEMALE; FEVER; HUMAN; MALE; NERVE SHEATH TUMOR; NEUTROPENIA; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SCHOOL CHILD; THROMBOCYTOPENIA;

EID: 0033933199     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.13.2576     Document Type: Article

References (48)

1. Carpenter PA, White L, McCowage GB, et al: A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: A report from the Australia and New Zealand Children's Cancer Study Group. Cancer 80:489-496, 1997
2. Meresse V, Vassal G, Michon J. et al: Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: A phase II study from the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 11:630-637, 1993
3. Saleh RA, Graham-Pole J, Cassano W, et al: Response of osteogenic sarcoma to the combination of etoposide and cyclophosphamide as neoadjuvant chemotherapy. Cancer 65:861-865, 1990
4. White L, McCowage G, Kannourakis G, et al: Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: A phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group. J Clin Oncol 12:522-531, 1994
5. Brock N: The oxazaphosphorines. Cancer Treat Rev 10:3-15, 1983 (suppl A)
6. Yule SM, Boddy AV, Cole M, et al: Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol 41:13-19, 1996
7. Ren S, Kalhorn TF, McDonald GB, et al: Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther 64:289-301, 1998
8. Tasso MJ, Boddy AV, Price L, et al: Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients. Cancer Chemother Pharmacol 30:207-211, 1992
9. Busse D, Busch FW, Bohnenstengel F, et al: Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism. J Clin Oncol 15:1885-1896, 1997
10. Busse D, Busch FW, Schweizer E, et al: Fractionated administration of high-dose cyclophosphamide: Influence on dose-dependent changes in pharmacokinetics and metabolism. Cancer Chemother Pharmacol 43:263-268, 1999
11. Teicher BA, Holden SA, Eder JP, et al: Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo. Cancer Res 49:5994-5998, 1989
12. O'Dwyer PJ, Leyland-Jones B, Alonso MT, et al: Etoposide (VP-16-213): Current status of an active anticancer drug. N Engl J Med 312:692-700, 1985
13. Lilley ER, Rosenberg MC, Elion GB, et al: Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft. Cancer Res 50:284-287, 1990
14. Gentet JC, Brunat-Mentigny M, Demaille MC, et al: Ifosfamide and etoposide in childhood osteosarcoma: A phase II study of the French Society of Paediatric Oncology. Eur J Cancer 33:232-237, 1997
15. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333-1340, 1989
16. Jurgens H, Exner U, Kuhl J. et al: High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma. Cancer Chemother Pharmacol 24:S40-S44, 1989 (suppl 1)
17. Meyer WH, Kun L, Marina N, et al: Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. J Clin Oncol 10:1737-1742, 1992
18. Wexler LH, DeLaney TF, Tsokos M, et al: Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer 78:901-911, 1996
19. Cairo MS: The use of ifosfamide, carboplatin, and etoposide in children with solid tumors. Semin Oncol 22:23-27, 1995
20. Fields KK, Zorsky PE, Hiemenz JW, et al: Ifosfamide, carboplatin, and etoposide: A new regimen with a broad spectrum of activity. J Clin Oncol 12:544-552, 1994
21. Miser JS, Kinsella TJ, Triche TJ, et al: Ifosfamide with mesna uroprotection and etoposide: An effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 5:1191-1198, 1987
22. Treuner J, Koscielniak E, Keim M: Comparison of the rates of response to ifosfamide and cyclophosphamide in primary unresectable rhabdomyosarcomas. Cancer Chemother Pharmacol 24:S48-S50, 1989 (suppl 1)
23. Craft A, Cotterill S, Malcolm A. et al: Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 16:3628-3633, 1998
24. Kung FH, Pratt CB, Vega RA, et al: Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood: A Pediatric Oncology Group Phase II study. Cancer 71:1898-1903, 1993
25. Kung FH, Desai SJ, Dickerman JD, et al: Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: A Pediatric Oncology Group phase I/II study. J Pediatr Hematol Oncol 17:265-269, 1995
26. Yalcin S, Gullu I, Barista I, et al: Treatment of advanced refractory sarcomas with ifosfamide and etoposide combination chemotherapy. Cancer Invest 16:297-302, 1998
27. Blair SC, Zalupski MM, Baker LH: Ifosfamide and etoposide in the treatment of advanced soft tissue sarcomas. Am J Clin Oncol 17:480-484, 1994
28. Edmonson JH, Buckner JC, Long HJ, et al: Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas. J Natl Cancer Inst 81:863-866, 1989
29. Kushner BH, Meyers PA, Gerald WL. et al: Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol 13:2796-2804, 1995
30. Clark PI, Slevin ML, Joel SP, et al: A randomized trial of two etoposide schedules in small-cell lung cancer: The influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12:1427-1435, 1994
31. Brade WP, Herdrich K, Varini M: Ifosfamide: Pharmacology, safety and therapeutic potential. Cancer Treat Rev 12:1-47, 1985
32. Bramwell VH, Mouridsen HT, Santoro A, et al: Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 23:311-321, 1987
33. Bramwell VH, Mouridsen HT, Santoro A, et al: Cyclophosphamide versus ifosfamide: A randomized phase II trial in adult soft-tissue sarcomas: The European Organization for Research and Treatment of Cancer [EORTC]. Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 31:S180-S184, 1993 (suppl 2)
34. Maurer HM, Gehan EA, Beltangady M, et al: The Intergroup Rhabdomyosarcoma Study-II. Cancer 71:1904-1922, 1993
35. Crist W, Gehan EA, Ragab AH, et al: The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 13:610-630, 1995
36. Ruymann FB, Vietti T, Gehan E, et al: Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma: A pilot study without hematopoietic growth factor support evaluating toxicity and response. J Pediatr Hematol Oncol 17:331-337, 1995
37. Kamen BA, Frenkel E, Colvin OM: Ifostamide: Should the honeymoon be over? J Clin Oncol 13:307-309, 1995
38. Oberlin O, Habrand JL, Zucker JM, et al: No benefit of ifosfamide in Ewing's sarcoma: A nonrandomized study of the French Society of Pediatric Oncology. J Clin Oncol 10:1407-1412, 1992
39. Shaw PJ, Eden T: Ifosfamide in paediatric oncology: Tried but not tested? Lancet 335:1022-1023, 1990
40. Kurowski V, Wagner T: Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloracetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother Pharmacol 33:36-42, 1993
41. Wagner T: Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 26:439-456, 1994
42. Bryant BM, Jarman M, Ford HT, et al: Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 2:657-659, 1980
43. Brock N, Pohl J: The development of mesna for regional detoxification. Cancer Treat Rev 10:33-43, 1983 (suppl A)
44. Pratt CB, Green AA, Horowitz ME, et al: Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol 4:1253-1261, 1986
45. Canpolat C, Pearson P, Robertson R, et al: Ifosfamide tolerance in osteosarcoma patients previously treated with cis-diamminedichloroplatinum-II: Renal, hematologic, and neurologic observations. Med Pediatr Oncol 26:36-47, 1996
46. Skinner R, Sharkey IM, Pearson AD, et al: Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol 11:173-190, 1993
47. Suarez A, McDowell H, Niaudet P, et al: Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: An International Society of Pediatric Oncology report. J Clin Oncol 9:2177-2182, 1991
48. Beckwith C, Flaharty KK, Cheung AK, et al: Fanconi's syndrome due to ifosfamide. Bone Marrow Transplant 11:71-73, 1993